Lisa Zimmer
German Cancer Research Center(DE)Heidelberg University(DE)Düsseldorf University Hospital(DE)National Center for Tumor Diseases(DE)Dana-Farber Cancer Institute(US)Essen University Hospital(DE)University Dermatology(US)Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie(DE)DKFZ-ZMBH Alliance(DE)West German Heart and Vascular Center Essen(DE)Deutschen Konsortium für Translationale Krebsforschung(DE)Heinrich Heine University Düsseldorf(DE)University of Duisburg-Essen(DE)Oberlin College(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Genomic correlates of response to CTLA-4 blockade in metastatic melanoma(2015)2,936 cited
- → Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma(2019)1,063 cited
- → The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma(2013)931 cited
- → Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial(2012)901 cited
- → Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy(2016)638 cited
- → Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy(2016)556 cited